Celldex Therapeutics, Inc.(CLDX)

Description: Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. The company has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused precision targeted immunotherapy platform. Its lead drug candidates include rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma and a Phase II study for the treatment of recurrent glioblastoma; and CDX-011, an antibody-drug conjugate, which completed a randomized Phase IIb study for the treatment of advanced breast cancer. The company also has various earlier stage candidates in clinical development, such as CDX-1135, a molecule that inhibits a part of the immune system called the complement system; CDX-1127, a therapeutic fully human monoclonal antibody for cancer indications that is in Phase I study in patients with selected malignant solid tumors or hematologic cancers; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor, which completed Phase I study in healthy subjects; and CDX-1401, an antibody-targeted technology program for cancer indications that completed Phase I study in combination with toll-like receptor agonists poly-ICLC. Its preclinical product candidate includes CDX-014, a human monoclonal antibody-drug conjugate that targets TIM-1, a molecule that is expressed on renal and ovarian cancers with minimal expression in normal tissues. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Thomas Jefferson University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. Celldex Therapeutics, Inc. was founded in 1983 and is headquartered in Needham, Massachusetts.

---

Keywords: Medicine Biotechnology Cancer Biopharmaceutical Clinical Medicine Immunology Solid Tumors Immune System Immunotherapy Treatment Of Cancer Breast Cancer Monoclonal Antibodies Cancer Treatment Clinical Development Monoclonal Antibody Ovarian Cancer Genetics Treatment Of Breast Cancer Glioblastoma Blastoma Brain Tumor Antibody Drug Conjugate Cancer Center Cancer Research Pivotal Complement System Hematologic Cancers Advanced Breast Cancer Dendritic Cell Recurrent Glioblastoma Targeted Immunotherapy Cdx 301 Rockefeller University

---

Home Page: www.celldex.com

CLDX Technical Analysis

Perryville III Building
Hampton, NJ 08827
United States
Phone: 908 200 7500

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)